CYT387 is a small-molecule, ATP-competitive JAK1/JAK2 inhibitor with IC50 of 11 and 18 nM respectively. CYT387 inhibits growth of Ba/F3-JAK2V617F and human erythroleukemia (HEL) cells (IC (50) approximately 1500 nM) or Ba/F3-MPLW515L cells (IC (50)=200 nM), but has considerably less activity against BCR-ABL harboring K562 cells (IC50=58000 nM).
|Cell lines||Ba/F3 cells expressing JAK2V617F (Ba/F3-JAK2V617F) and MPLW515L (Ba/F3–MPLW515L) mutants, as well as CHRF-288-11 (JAK2T875N) and CMK (JAK3A572V) cells|
|Preparation method||Cell-based assays. Ba/F3 cells expressing JAK2V617F (Ba/F3-JAK2V617F) and MPLW515L (Ba/F3–MPLW515L) mutants, as well as CHRF-288-11 (JAK2T875N) and CMK (JAK3A572V) cells were generously provided by D Gary Gilliland (Brigham and Women’s Hospital, Boston, MA, USA). The TEL/JAK2 and TEL/ JAK3 fusions were generated and introduced into Ba/F3 murine cells as described earlier. The TEL/JAK2- or TEL/JAK3-transfected cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal calf serum (FCS). Ba/F3 wild-type cells were cultured in RPMI containing 10% FCS supplemented with 5 ng/ml murine IL-3 (Peprotech, Rocky Hill, NJ, USA). Proliferation was measured using the Alamar Blue assay (TREK Diagnostic Systems, Cleveland, OH, USA) after incubating for 72 h at 37℃with 5% CO2.|
|Incubation time||72 h|
|Animal models||murine model of JAK2V617F-dependent MPN|
|Formulation||dissolved in NMP (120 mg/mL final; 1-methyl-2-pyrrolidinone, Chromasolv Plus; Sigma-Aldrich). Subsequently, the CYT387/NMP mix was diluted with 0.14M Captisol (Cydex Pharmaceuticals Inc) to a concentration of 6 mg/mL and further diluted with 0.1M Captisol to a final concentration of 4 mg/mL.|
|Dosages||25, 50mg/kg twice daily from day 34 to day 82|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Source||Pharmacol Res (2013). Figure 3. CYT387|
|Incubation Time||24 h|
|Results||Neither absence of Mdr1a/1bnor of Bcrp1 showed a significant effect on the overall plasma expo-sure between 0 and 8 h.|
|Source||Pharmacol Res (2013). Figure 2. CYT387|
|Cell Lines||MDCK-II cells|
|Incubation Time||2,4 and 8 h|
|Results||In the MDCKII parental cell line, there was a mod-est apically directed transport of CYT387 (transport ratio r = 1.2),which was abrogated with the MDR1-specific inhibitor zosuquidar(Fig. 2A and B), suggesting that this background transport wasmediated by endogenous canine MDR1 present in the MDCKII cells.|
Liquid chromatography-tandem mass spectrometric assay for the JAK2 inhibitor CYT387 in plasma.
Sparidans et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 May 1;895-896:174-7. PMID: 22476054.
The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.
Monaghan et al. Leukemia. 2011 Dec;25(12):1891-9. PMID: 21788946.
CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms.
Tyner et al. Blood. 2010 Jun 24;115(25):5232-40. PMID: 20385788.
CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
Pardanani et al. Leukemia. 2009 Aug;23(8):1441-5. PMID: 19295546.
|Related JAK Products|
PF-06651600 is a potent and irreversible JAK3-selective inhibitor with an IC50 of 33.1 nM but without activity (IC50 > 10 000 nM) against JAK1, JAK2, and TYK2.
Upadacitinib (ABT-494) is a potent and selective Janus kinase (JAK) 1 inhibitor being developed for the treatment of several autoimmune disorders with an IC50 of 43 nM.
Ruxolitinib phosphate(INCB018424 phosphate) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3.
Oclacitinib is a novel inhibitor of JAK family members with IC50 ranging from 10 to 99 nM and JAK1-dependent cytokines with IC50 ranging from 36 to 249 nM, which did not inhibit a panel of 38 non-JAK kinases.
Baricitinib phosphate(INCB 028050; LY 3009104) is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.